12:00 AM
 | 
Jul 27, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tygacil tigecycline: Phase III data

Wyeth disclosed in the conference call accompanying its 2Q09 earnings statement that a Phase III trial of Tygacil to treat diabetic foot ulcers missed...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >